PDF(Pubmed)
Abstract：
Pneumococcal serogroups consist of structurally related serotypes, and serotype-specific antibodies can cross-react against other serotypes within the same serogroup. Cross-reactivity of vaccine-induced serotype 6A antibodies, and, to a lesser extent, serotype 6B antibodies, to serotype 6C has been demonstrated following receipt of the 13-valent pneumococcal conjugate vaccine (PCV13), which contains serotypes 6A and 6B. V114 is a 15-valent PCV containing the 13 PCV13 serotypes plus two additional serotypes, 22F and 33F. This study assessed cross-reactivity to serotype 6C in recipients of V114 and PCV13 as well as specificity of opsonophagocytic activity (OPA) responses in serogroup 6. Following receipt of V114 or PCV13, the observed OPA geometric mean titers to serotypes 6A, 6B, and 6C were comparable across both vaccination groups (post-single dose in adults ≥50 years of age [n = 250] and from pre- to post-dose 4 in pediatric participants 12-15 months of age [n = 150]). Based on OPA inhibition studies, V114 induced cross-reactive antibodies to serotype 6C in adult and pediatric populations that were specific and comparable to those induced by PCV13. Based on experience with PCV13, V114 may also provide comparable protection against pneumococcal disease caused by serotype 6C; however, this will have to be evaluated in real-world studies.
摘要：
肺炎球菌血清组由结构相关的血清型组成，和血清型特异性抗体可以与相同血清群内的其他血清型交叉反应。疫苗诱导的血清型6A抗体的交叉反应性，and,在较小程度上，血清型6B抗体，在接受13价肺炎球菌结合疫苗（PCV13）后，已证明血清型6C，其含有血清型6A和6B。V114是含有13种PCV13血清型加上另外两种血清型的15价PCV,22F和33F。这项研究评估了V114和PCV13受体对血清型6C的交叉反应性，以及血清群6中调理吞噬活性（OPA）反应的特异性。收到V114或PCV13后，观察到的OPA几何平均滴度为血清型6A，6B,和6C在两个疫苗接种组之间具有可比性(在50岁以上的成人中单次给药后[n=250],在12~15月龄的儿科参与者中从给药前到给药后4[n=150]).基于OPA抑制研究，V114在成人和儿科人群中诱导针对血清型6C的交叉反应性抗体，这些抗体具有特异性，并且与PCV13诱导的抗体相当。根据PCV13的经验，V114还可以为由血清型6C引起的肺炎球菌疾病提供类似的保护；然而，这必须在现实世界的研究中进行评估。
